* less than 65 years of age * symptom onset, or positive pcr (whichever comes first), more than 7 days (168 hours) prior to planned plasma infusion. * severe dementia, or other significant comorbidity, that generates a serious deterioration of the baseline functional status, with a life expectancy of less than 6 months. * participation in another clinical trial or study. * history of allergy to amotosalen or psoralens

* less than 65 years of age * symptom onset, or positive pcr (whichever comes first), more than 7 days (168 hours) prior to planned plasma infusion. * severe dementia, or other significant comorbidity, that generates a serious deterioration of the baseline functional status, with a life expectancy of less than 6 months. * participation in another clinical trial or study. * history of allergy to amotosalen or psoralens

less than 65 years of age symptom onset, or positive pcr (whichever comes first), more than 7 days (168 hours) prior to planned plasma infusion. severe dementia, or other significant comorbidity, that generates a serious deterioration of the baseline functional status, with a life expectancy of less than 6 months. participation in another clinical trial or study. history of allergy to amotosalen or psoralens

less than 65 years of age symptom onset, or positive pcr (whichever comes first), more than 7 days (168 hours) prior to planned plasma infusion. severe dementia, or other significant comorbidity, that generates a serious deterioration of the baseline functional status, with a life expectancy of less than 6 months. participation in another clinical trial or study. history of allergy to amotosalen or psoralens